It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To achieve therapeutic goals, many cancer chemotherapeutics are used at doses close to their maximally tolerated doses. Thus, it may be expected that when therapies are combined at therapeutic doses, toxicity profiles may change. In many ways, prediction of synergistic toxicities for drug combinations is similar to predicting synergistic efficacy, and is dependent upon building hypotheses from molecular mechanisms of drug toxicity. The key objective of this initiative was to generate and make publicly available key high-content data sets for mechanistic hypothesis generation as it pertains to a unique toxicity profile of a drug pair for several anticancer drug combinations. The expectation is that tissue-based genomic information that are derived from target tissues will also facilitate the generation and testing of mechanistic hypotheses. The view is that availability of these data sets for bioinformaticians and other scientists will contribute to analysis of these data and evaluation of the approach.
Design Type(s) | drug design objective • stimulus or stress design • microarray data analysis objective |
Measurement Type(s) | response to drug |
Technology Type(s) | microarray |
Factor Type(s) | animal body part • experimental condition |
Sample Characteristic(s) | Rattus norvegicus • bone marrow • heart • liver • kidney • skin of body |
Machine-accessible metadata file describing the reported data (ISA-Tab format)
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Toxicology and Pharmacology Branch, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) ; Present address: Discovery Toxicology, Bristol-Myers Squibb, Princeton, NJ, 08540, USA., (GRID:grid.419971.3)
2 Toxicology and Pharmacology Branch, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
3 Kelly Government Solutions, Research Triangle Park, NC, USA (GRID:grid.48336.3a) ; Integrative Bioinformatics Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA (GRID:grid.280664.e) (ISNI:0000 0001 2110 5790) ; Microarray and Genome Informatics Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA (GRID:grid.280664.e) (ISNI:0000 0001 2110 5790)
4 Microarray and Genome Informatics Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA (GRID:grid.280664.e) (ISNI:0000 0001 2110 5790) ; Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, Division of Intramural Research, NC, USA (GRID:grid.280664.e) (ISNI:0000 0001 2110 5790)